AML - 712
Revumenib plus intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated phase 1 results from SNDX-5613-0708
Ibrahim Aldoss
Poster Presenter: Ibrahim Aldoss
1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
Showing 1 result for author "Ibrahim Aldoss".
AML - 712
Ibrahim Aldoss
Poster Presenter: Ibrahim Aldoss
This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.